IFNA2 and cryohydrocytosis: There are a number of demographical, laboratory, histological, genetical and virological predictors for the treatment of CHC patients with Peg-IFN-α and RBV [21, 22, 35, 36] or with Peg-IFN-α, RBV and one of the first-generation protease inhibitors [37].